IPOs
Filter News
Found 17,230 articles
-
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - April 18, 2024
4/18/2024
Schrödinger, Inc. today reported that on April 15, 2024, the company granted (i) non-statutory stock options to purchase 3,600 shares of the company’s common stock to three newly hired employees and (ii) restricted stock units (RSUs) with respect to 9,613 shares of the company’s common stock to nine newly hired employees.
-
Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million
4/18/2024
Benitec Biopharma Inc. today announced a $40.0 million private investment in public equity (PIPE) financing from the sale of 5,749,152 shares of its common stock at a price per share.
-
Windtree Therapeutics Announces Reverse Stock Split - April 18, 2024
4/18/2024
Windtree Therapeutics, Inc. today announced that the Company’s Board of Directors has approved a 1-for-18 reverse stock split of its issued and outstanding common stock, par value of $0.001 per share (the “Reverse Stock Split”).
-
Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)
4/17/2024
Allarity Therapeutics, Inc today announced that it had been granted an extension until May 14, 2024, to regain compliance with Nasdaq Listing Rule 5550(b)(1).
-
Allurion Closes $48 Million Convertible Senior Secured Note Financing with RTW Investments
4/17/2024
Allurion Technologies, Inc. today announced the closing of a $48 million convertible senior secured note financing with certain entities managed by RTW Investments, LP (“RTW”).
-
Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds
4/17/2024
Longeveron Inc. today announced that it has entered into definitive agreements for the exercise of certain existing warrants to purchase an aggregate of 2,399,744 shares.
-
Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering
4/16/2024
Calidi Biotherapeutics, Inc. today announced the pricing of its “reasonable best efforts” public offering of 15,197,500 shares of common stock (or pre-funded warrants in lieu thereof) and accompanying Series A Common Warrants.
-
Sunshine Biopharma Announces Reverse Stock Split
4/12/2024
Sunshine Biopharma, Inc. announced today a one for one hundred reverse split of its common stock, effective at market open on April 17, 2024.
-
bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/11/2024
bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Compensation Committee of the Company’s Board of Directors approved inducement grants of 102,700 restricted stock units (“RSUs”) to twelve newly hired employees with a grant date of April 9, 2024 (the “Inducement Grants”).
-
Leap Therapeutics Announces $40 Million Private Placement
4/11/2024
Leap Therapeutics, Inc. today announced it has entered into a securities purchase agreement with a select group of institutional investors to issue and sell an aggregate of 12,660,993 shares of its common stock ("Common Stock") at a price of $2.82 per share and pre-funded warrants to purchase 1,523,404 shares of Common Stock at a price of $2.819 per share of Common Stock.
-
IMUNON Reports Compliance with Nasdaq Listing Requirements
4/11/2024
IMUNON, Inc. today announced that on April 10, 2024, it received written notice from the staff of The NASDAQ Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) for continued listing on The Nasdaq Capital Market.
-
Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering
4/11/2024
Aptevo Therapeutics Inc. today announced the pricing of a public offering of (i) 3,400,000 shares of its common stock or pre-funded warrants in lieu thereof and (ii) warrants to purchase up to an aggregate of 6,800,000 shares of its common stock.
-
Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market
4/11/2024
Oculis Holding AG (Nasdaq Global Market: OCS) (“Oculis” or the “Company”), today announced that on April 11, 2024 it completed a financing of approximately $59 million, consisting of the issuance of 5,000,000 of its ordinary shares, nominal value CHF 0.01 per share (the “Shares”) at a purchase price of $11.75 per Share.
-
Skye Bioscience Uplists to The Nasdaq Global Market
4/10/2024
Skye Bioscience, Inc. announced today that the Company has received approval to list its common stock on the Nasdaq Global Market® stock exchange ("Nasdaq").
-
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - April 10, 2024
4/10/2024
BridgeBio Pharma, Inc. today announced that on April 5, 2024, the compensation committee of BridgeBio’s board of directors approved equity grants to 19 new employees in restricted stock units for an aggregate of 93,088 shares of the Company’s common stock.
-
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics
4/9/2024
Ocular Therapeutix, Inc. today announced that it has granted inducement equity awards to its newly appointed Senior Vice President, Global Head of Biometrics, Liansheng Zhu.
-
TRACON Pharmaceuticals Announces Reverse Stock Split - April 8, 2024
4/8/2024
TRACON Pharmaceuticals today announced that, following stockholder approval at the special meeting of stockholders held on September 6, 2023 of a proposal authorizing the board of directors of the Company.
-
Jaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement
4/8/2024
Jaguar Health, Inc. today announced that on April 5, 2024 the Company received formal notice that the Listing Qualifications Staff of The Nasdaq Stock Market LLC has granted Jaguar an additional grace period, through August 13, 2024, to regain compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market.
-
Contineum Therapeutics priced its initial public offering Friday, scaling back its expectations for gross proceeds of $110 million for clinical trials of a challenger to Boehringer Ingelheim and Roche.
-
Contineum Therapeutics Announces Pricing of Initial Public Offering - April 05, 2024
4/5/2024
Contineum Therapeutics, Inc. announced the pricing of its initial public offering of 6,875,000 shares of its Class A common stock at a price to the public of $16.00 per share.